inlyta- axitinib tablet, film coated
pfizer laboratories div pfizer inc - axitinib (unii: c9lvq0yuxg) (axitinib - unii:c9lvq0yuxg) - axitinib 1 mg - inlyta as a single agent is indicated for the treatment of advanced rcc after failure of one prior systemic therapy. none. risk summary based on findings in animal studies and its mechanism of action, inlyta can cause fetal harm when administered to a pregnant woman. there are no available human data to inform the drug-associated risk. in developmental toxicity studies, axitinib was teratogenic, embryotoxic and fetotoxic in mice at exposures lower than human exposures at the recommended starting dose (see error! hyperlink reference not valid. ) . advise females of reproductive potential of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the united states (u.s.) general population of major birth defects is 2%–4% and of miscarriage is 15%–20% of clinically recognized pregnancies. when inlyta is used in combination with avelumab or pembrolizumab, refer to the full prescribing information of avelu
inlyta- axitinib tablet, film coated
u.s. pharmaceuticals - axitinib (unii: c9lvq0yuxg) (axitinib - unii:c9lvq0yuxg) - axitinib 5 mg - inlyta in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (rcc). inlyta in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced rcc. inlyta as a single agent is indicated for the treatment of advanced rcc after failure of one prior systemic therapy. none. risk summary based on findings in animal studies and its mechanism of action, inlyta can cause fetal harm when administered to a pregnant woman. there are no available human data to inform the drug-associated risk. in developmental toxicity studies, axitinib was teratogenic, embryotoxic and fetotoxic in mice at exposures lower than human exposures at the recommended starting dose (see data) . advise females of reproductive potential of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the united states (u.s.) general population of maj
axitinib synthon 1 mg film-coated tablets
synthon bv microweg 22, 6545 cm nijmegen, netherlands - film-coated tablet - axitinib 1 mg - antineoplastic agents
axitinib synthon 3 mg film-coated tablets
synthon bv microweg 22, 6545 cm nijmegen, netherlands - film-coated tablet - axitinib 3 mg - antineoplastic agents
axitinib synthon 5 mg film-coated tablets
synthon bv microweg 22, 6545 cm nijmegen, netherlands - film-coated tablet - axitinib 5 mg - antineoplastic agents
axitinib synthon 7 mg film-coated tablets
synthon bv microweg 22, 6545 cm nijmegen, netherlands - film-coated tablet - axitinib 7 mg - antineoplastic agents
inlyta axitinib 5 mg tablet blister pack
pfizer australia pty ltd - axitinib, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy
inlyta axitinib 1 mg tablet blister pack
pfizer australia pty ltd - axitinib, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide red - for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
inlyta 1 mg
pfizer pharmaceuticals israel ltd - axitinib - film coated tablets - axitinib 1 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.
inlyta 5 mg
pfizer pharmaceuticals israel ltd - axitinib - film coated tablets - axitinib 5 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.